These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17319789

  • 1. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
    Dvorácková J, Uvírová M.
    Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB.
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [Abstract] [Full Text] [Related]

  • 3. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y.
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [Abstract] [Full Text] [Related]

  • 4. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB, Qian J, Lieber MM, Bostwick DG.
    Cancer Res; 1997 Feb 01; 57(3):524-31. PubMed ID: 9012485
    [Abstract] [Full Text] [Related]

  • 5. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB.
    Mod Pathol; 2002 Jan 01; 15(1):35-44. PubMed ID: 11796839
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [The molecular genetic assessment of prognostic factors in carcioma of the prostate: a pilot study].
    Dvorácková J, Uvírová M.
    Cesk Patol; 2006 Jul 01; 42(3):130-2. PubMed ID: 16955560
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, Cathelineau X, Cussenot O.
    Hum Pathol; 2013 Aug 01; 44(8):1617-23. PubMed ID: 23574779
    [Abstract] [Full Text] [Related]

  • 12. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, Klein EA, Levin HS, Zippe CD, Tubbs RR.
    Hum Pathol; 2001 Dec 01; 32(12):1392-7. PubMed ID: 11774175
    [Abstract] [Full Text] [Related]

  • 13. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.
    Exp Mol Pathol; 1999 Jun 01; 66(2):140-8. PubMed ID: 10409442
    [Abstract] [Full Text] [Related]

  • 14. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
    Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM.
    Cancer Res; 2006 Nov 15; 66(22):10683-90. PubMed ID: 17108105
    [Abstract] [Full Text] [Related]

  • 15. [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
    Zeng X, Wu SF, Xu Q, Xiao Y, Liu TH.
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep 15; 35(9):523-8. PubMed ID: 17134545
    [Abstract] [Full Text] [Related]

  • 16. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7.
    Mian C, Lodde M, Comploj E, Palermo S, Lusuardi L, Marziani F, Chiocchetti A, Spada A, Mian M, Pycha A.
    Prostate; 2006 Jun 15; 66(9):966-70. PubMed ID: 16541423
    [Abstract] [Full Text] [Related]

  • 17. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR.
    Eur Urol; 2007 Jul 15; 52(1):116-25. PubMed ID: 17070983
    [Abstract] [Full Text] [Related]

  • 18. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
    Mark HF, Samy M, Santoro K, Mark S, Feldman D.
    Exp Mol Pathol; 2000 Feb 15; 68(1):65-9. PubMed ID: 10640455
    [Abstract] [Full Text] [Related]

  • 19. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
    Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ.
    Mod Pathol; 2001 Oct 15; 14(10):1030-5. PubMed ID: 11598174
    [Abstract] [Full Text] [Related]

  • 20. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
    Miura S, Nakashima M, Ito M, Kondo H, Meirmanov S, Hayashi T, Soda M, Matsuo T, Sekine I.
    Cancer; 2008 May 15; 112(10):2143-51. PubMed ID: 18348306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.